中访网数据 石药创新制药股份有限公司9月30日公告，公司与控股股东石药集团恩必普药业有限公司签署协议，拟以现金11亿元收购其持有的控股子公司石药集团巨石生物制药有限公司29%股权。交易完成后，石药创新对巨石生物的持股比例将从51%提升至80%。此次交易定价以评估机构出具的评估报告为依据，标的公司股东全部权益评估值为38.05亿元。巨石生物是一家专注于抗体类药物、ADC及mRNA疫苗等领域的创新生物医药企业，其恩朗苏拜单抗注射液与注射用奥马珠单抗已于2024年上市。公司表示，此次收购旨在深化在创新生物医药领域的战略布局，提升综合竞争力。该事项已获董事会审议通过，尚需股东大会批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.